About Rhythm Pharmaceuticals (NASDAQ:RYTM)
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.40) by $1.38. View Rhythm Pharmaceuticals' Earnings History.
Where is Rhythm Pharmaceuticals' stock going? Where will Rhythm Pharmaceuticals' stock price be in 2018?
4 brokerages have issued 1-year price targets for Rhythm Pharmaceuticals' stock. Their predictions range from $23.00 to $40.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $31.25 in the next year. View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)
- 2. Needham & Company LLC analysts commented, "Rhythm reported 3Q17 financial results and we spoke w/ mgmt for an update. Enrollment in Phase 3 setmelanotide trial in POMC Deficiency is still expected to be completed by YE17. We assume top-line results in early 2019 (unch) and continue to expect a positive outcome. Mgmt also reiterated guidance for intiation of Phase 3 setmelanotide trial in LepR Deficiency by YE17. Data in a small number of patients with POMC or LepR Deficiency were remarkably strong and are the basis for our enthusiasm for the drug and the stock. We await data from Phase 2 trials in Alstrom Syndrome and POMC Epigenetic/ Heterozygous mutation patients in early 2018. A favorable outcome would add meaningfully to peak sales potential. BUY." (11/14/2017)
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include ARMO Biosciences (ARMO), Prothena (PRTA), Xencor (XNCR), Clinigen Group (CLIN), Epizyme (EPZM), Acorda Therapeutics (ACOR), CytomX Therapeutics (CTMX), Audentes Therapeutics (BOLD), Zai Lab (ZLAB), Dermira (DERM), Dynavax Technologies (DVAX), Revance Therapeutics (RVNC), Solid Biosciences (SLDB), Intra-Cellular Therapies (ITCI), PTC Therapeutics (PTCT), Neuroderm (NDRM), Amarin (AMRN) and Athenex (ATNX).
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- David P. Meeker M.D., Chairman of the Board (Age 63)
- Keith Gottesdiener M.D., President, Chief Executive Officer, Director (Age 63)
- Hunter C. Smith, Chief Financial Officer, Treasurer (Age 49)
- Lex H.T. Van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
- Nithya Desikan, Chief Commercial Officer (Age 38)
- Fred T. Fiedorek M.D., Chief Medical Officer (Age 62)
- Neil Exter, Independent Director (Age 58)
- Todd Foley, Independent Director (Age 45)
- Christophe R. Jean, Independent Director (Age 61)
- Edward T. Mathers, Independent Director (Age 57)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
When does the company's lock-up period expire?
Rhythm Pharmaceuticals' lock-up period expires on Tuesday, April 3rd. Rhythm Pharmaceuticals had issued 7,050,000 shares in its public offering on October 5th. The total size of the offering was $119,850,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Who owns Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MPM Asset Management LLC (9.88%), Perceptive Advisors LLC (2.73%), ArrowMark Colorado Holdings LLC (1.70%), BlackRock Inc. (1.32%), Franklin Resources Inc. (0.91%) and Citadel Advisors LLC (0.74%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.
Who bought Rhythm Pharmaceuticals stock? Who is buying Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, BlackRock Inc., Franklin Resources Inc., Citadel Advisors LLC, Geode Capital Management LLC and Rock Springs Capital Management LP. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.
How do I buy Rhythm Pharmaceuticals stock?
Shares of Rhythm Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of Rhythm Pharmaceuticals stock can currently be purchased for approximately $27.61.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $711.03 million. Rhythm Pharmaceuticals employs 15 workers across the globe.
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (RYTM)MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings History and Estimates Chart
Rhythm Pharmaceuticals (NASDAQ RYTM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.63 EPS
Next Year EPS Consensus Estimate: $-2.05 EPS
Dividend History for Rhythm Pharmaceuticals (NASDAQ:RYTM)
No dividend announcements for this company have been tracked by MarketBeat.com
Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 56.47%
Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/10/2017||David P Meeker||Director||Buy||25,000||$17.00||$425,000.00|| |
|10/10/2017||James E Flynn||Insider||Buy||355,000||$17.00||$6,035,000.00|| |
|10/10/2017||S.A. Ipsen||Major Shareholder||Buy||20,000||$17.00||$340,000.00|| |
|10/5/2017||Bros. Advisors Lp Baker||Insider||Buy||885,000||$17.00||$15,045,000.00|| |
Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines
|Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per Share|
www.americanbankingnews.com - February 22 at 5:10 AM
| Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages|
www.americanbankingnews.com - February 18 at 5:24 AM
| Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS|
www.americanbankingnews.com - February 14 at 3:18 AM
|Rhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClub|
www.americanbankingnews.com - February 4 at 6:22 AM
|Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - February 2 at 7:22 PM
|Rhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClub|
www.americanbankingnews.com - January 29 at 10:42 PM
|Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per Share|
www.americanbankingnews.com - January 25 at 11:41 AM
|Critical Analysis: Rhythm Pharmaceuticals (RYTM) versus The Competition|
www.americanbankingnews.com - January 10 at 11:14 PM
|Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - January 9 at 9:46 PM
|WuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of Obesity|
finance.yahoo.com - January 9 at 6:11 PM
|Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity|
finance.yahoo.com - January 4 at 8:49 AM
|Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 2 at 8:02 AM
|BidaskClub Downgrades Rhythm Pharmaceuticals (RYTM) to Hold|
www.americanbankingnews.com - December 29 at 6:32 AM
|Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - December 15 at 5:52 AM
| Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM)|
www.americanbankingnews.com - November 30 at 3:12 AM
|Rhythm Pharmaceuticals, Inc. (RYTM) Announces Earnings Results|
www.americanbankingnews.com - November 15 at 1:03 PM
| Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - November 15 at 9:47 AM
|General Electric Cuts 2018 EPS Target, Slashes Dividend - Presented by: The Aol. On Network|
www.nasdaq.com - November 15 at 7:54 AM
|Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 15 at 7:54 AM
|Rhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLC|
www.americanbankingnews.com - November 14 at 10:26 PM
|Rhythm Pharmaceuticals, Inc. (RYTM) Given "Buy" Rating at Cowen and Company|
www.americanbankingnews.com - November 14 at 10:26 PM
|Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team|
finance.yahoo.com - November 14 at 7:32 AM
|Rhythm Pharmaceuticals Breaks Through - Bhavneesh Sharma's Idea Of The Month|
seekingalpha.com - November 7 at 9:45 AM
|Rhythm Pharmaceuticals, Inc.'s Quiet Period To End on November 14th (NASDAQ:RYTM)|
www.americanbankingnews.com - November 7 at 1:26 AM
|9 Speculative Analyst Stocks With Projected Upside of 50% to 200%|
247wallst.com - November 4 at 6:13 PM
|Rhythm Pharmaceuticals: Today's Data Is Just The Beginning|
seekingalpha.com - November 1 at 3:26 PM
|Zacks: Analysts Set $31.00 Price Target for Rhythm Pharmaceuticals, Inc. (RYTM)|
www.americanbankingnews.com - October 31 at 10:22 AM
|Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome|
finance.yahoo.com - October 31 at 9:00 AM
|Morgan Stanley Initiates Coverage on Rhythm Pharmaceuticals, Inc. (RYTM)|
www.americanbankingnews.com - October 30 at 9:19 AM
|Rhythm Pharmaceuticals, Inc. (RYTM) Now Covered by Analysts at Needham & Company LLC|
www.americanbankingnews.com - October 30 at 8:09 AM
|Rhythm Pharmaceuticals, Inc. (RYTM) Earns Buy Rating from Analysts at Bank of America Corporation|
www.americanbankingnews.com - October 30 at 8:08 AM
|Orphan Disease IPO, Rhythm Pharmaceuticals: Initiating Coverage With Buy Rating And $34 Price Target (40% Upside)|
seekingalpha.com - October 27 at 3:45 PM
|Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - October 11 at 7:22 AM
|This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company|
finance.yahoo.com - October 11 at 7:22 AM
|Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Director Buys 25,000 Shares of Stock|
www.americanbankingnews.com - October 10 at 7:38 PM
|Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Major Shareholder Purchases 20,000 Shares of Stock|
www.americanbankingnews.com - October 10 at 7:38 PM
|Rhythm Pharmaceuticals Inc (RYTM) Insider Buys $6,035,000.00 in Stock|
www.americanbankingnews.com - October 10 at 1:32 PM
|IPO News This Week: Online Auto Marketplace, CarGurus, Tops the List|
finance.yahoo.com - October 9 at 2:16 AM
|Rhythm Pharmaceutical (RYTM) IPO Opens Up 37%|
www.streetinsider.com - October 6 at 8:52 PM
|Switch Keeps Recent IPO Market Momentum Going|
finance.yahoo.com - October 6 at 8:52 PM
|Bros. Advisors Lp Baker Purchases 885,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock|
www.americanbankingnews.com - October 6 at 7:24 PM
|Rhythm Pharmaceuticals (RYTM) Plans to Raise $100 Million in October 5th IPO|
www.americanbankingnews.com - September 27 at 1:18 AM
Rhythm Pharmaceuticals (NASDAQ:RYTM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Income Statement, Balance Sheet and Cash Flow Statement
Rhythm Pharmaceuticals (NASDAQ RYTM) Stock Chart for Saturday, February, 24, 2018